TELUS Proprietary
45
Key messages
1. Continued growth across various
therapeutic categories can be balanced
with plan sustainability tools.
2. Costs to treat rare diseases continue to
grow but may be mitigated by future
provincial/federal rare disease programs.
3. Impact of biosimilar molecules is
leading to cost relief across
specialty drugs.
4. Future pipeline can add to cost pressures but
also provide cost relief.
